Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.76 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4647949 | 1.00 | F10 (0.76) | F10GRM2MAOBMAOALMNA | |
| SCHEMBL28809355 | 0.88 | F10 (0.60) | F10GRM2MAOBMAOALMNA | |
| SCHEMBL28809356 | 0.88 | F10 (0.60) | F10GRM2MAOBMAOALMNA | |
| SCHEMBL13367795 | 0.87 | F10 (0.59) | F10GRM2 | |
| SCHEMBL455793 | 0.86 | F10 (1.00) | F10 | |
| SCHEMBL87178 | 0.86 | F10 (1.00) | F10 | |
| SCHEMBL15203246 | 0.86 | F10 (1.00) | F10 | |
| SCHEMBL7838893 | 0.86 | F10 (0.61) | F10GRM2MAOBMAOA | |
| SCHEMBL7838895 | 0.86 | F10 (0.61) | F10GRM2MAOBMAOA | |
| SCHEMBL13159149 | 0.86 | F10 (0.61) | F10GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960374-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-08-27 | — | — | EP | claimed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007064818-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-07 | — | — | WO | claimed |
| EP-3565552-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIVAROXABAN INVOLVING NOVEL INTERMEDIATE | UNICHEM LAB LTD (IN) | 2022-05-11 | — | — | EP | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100137274-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER SCHERING PHARMA AG (DE) | 2010-06-03 | — | — | US | disclosed |
| US-7592339-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007064818-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064818-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885GRM2 4486/4885MAOB 282/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885GRM2 4486/4885MAOB 282/4885 |
| US-20100137274-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885GRM2 4486/4885MAOB 282/4885 |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885GRM2 4486/4885MAOB 282/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885GRM2 4486/4885MAOB 282/4885 |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | MLLT3, DAO, FHIT | F10 1266/4885GRM2 3664/4885MAOB 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.